Eurizon Capital SGR S.p.A. Takes $13.69 Million Position in Edwards Lifesciences Corporation $EW

Eurizon Capital SGR S.p.A. bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 160,278 shares of the medical research company’s stock, valued at approximately $13,694,000.

Several other hedge funds and other institutional investors have also made changes to their positions in EW. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after acquiring an additional 4,108,270 shares in the last quarter. Viking Global Investors LP purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at about $238,688,000. AQR Capital Management LLC boosted its holdings in shares of Edwards Lifesciences by 114.5% in the third quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company’s stock valued at $161,055,000 after acquiring an additional 1,111,139 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Edwards Lifesciences by 1,952.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,149,700 shares of the medical research company’s stock valued at $98,012,000 after acquiring an additional 1,093,692 shares in the last quarter. Finally, Schroder Investment Management Group boosted its holdings in shares of Edwards Lifesciences by 1,657.4% in the third quarter. Schroder Investment Management Group now owns 1,133,475 shares of the medical research company’s stock valued at $88,150,000 after acquiring an additional 1,068,979 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on EW. Piper Sandler reiterated an “overweight” rating and issued a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the company an “outperform” rating in a research note on Monday, April 13th. UBS Group reiterated a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Truist Financial set a $90.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Finally, Wells Fargo & Company raised their price objective on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $95.65.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $80.98, for a total transaction of $82,518.62. Following the completion of the transaction, the vice president owned 33,934 shares in the company, valued at approximately $2,747,975.32. The trade was a 2.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at approximately $3,371,239.08. The trade was a 24.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 95,057 shares of company stock worth $7,874,217. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $86.41 on Monday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The stock has a market cap of $49.76 billion, a P/E ratio of 45.96, a PEG ratio of 2.17 and a beta of 0.87. The company has a 50-day moving average of $81.73 and a two-hundred day moving average of $83.00. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $88.28.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.